Analysis of the mechanism of inhibition of liver metastasis from colon cancer ------The role of Interleukin 2 receptor of the liver sinusoidal mononuclear cells

【目的】本研究在假设SMC管理的免疫系统在转移性肝癌（MLC）患者中受损的基础上，研究SMC和PBMC的特征。【材料与方法】采用流式细胞术分析7例肝癌切除术患者肝脏标本SMC和PBMC表面抗原。患者年龄35 ~ 80岁，男4例，女3例。原发病变为盲肠（2例）、升结肠（2例）和乙状结肠（3例）。在对照组，我们分析了健康候选人的PBMC。用MTT法评价对IL-2的反应。【结果】MLC患者CD3 (+) T细胞在PMBC中下降30%（50-60%：正常），在SMC中下降40%（50%：正常）。CD16 (+) NK细胞增加25-69%（正常20%）。3例PBMC CD4/CD8比值异常，CEA值高。与正常SMC（50%）相比，CD8和CD56双阳性细胞减少30%以下。IL-2R α链被诱导，但IL-2R β链在IL-2刺激后仍未被识别。【结论】在MLC中，SMC中CTL细胞减少，尤其是CEA值高的患者，可能显示免疫防御能力低于正常。CTL对IL-2的反应性也较低。经肝动脉或门静脉注射的免疫化疗可能是有效的，使用抗癌药物和额外的IL-2。该疗法会增加SMC内的CTL细胞，对il - 2r系统有良好的控制，影响肝转移患者治疗的良好效果。

[Purpose] in this study, we studied the characters of SMC and PBMC,based on the hypothesis that the immune system managed by sinusoidal mononuclear cells (SMC) was damaged in the patient bearing metastatic liver cancer (MLC).[Materials and methods] We analyzed the surface antigens on SMC and PBMC by flowcytometry in seven liver specimens taken from hepatectomized patients with MLC.The patients were aged from 35 to 80,4males and 3 females. Primary lesions were cecum (2), ascending colon (2) and 3 sigmoid colon (3). In the control group, we analized PBMC of healthy candidates. Response against IL-2 was assesed by MTT assay.[Results] In MLC patients, CD3 (+) T cell decreased to 30 % (50-60% : normal) in PMBC and 40% (50% : normal) in SMC.CD16 (+) NK cells increased to 25-69% (20% : normal). Abnormal CD4/CD8 ratio in PBMC were observed in three cases, who showed high CEA value.CD8 and CD56 double positive cells were decresed below 30% in comparison with normal SMC (50%). IL-2R alpha chain was induced, but IL-2R beta chain was not recognized even after IL-2 stimulation.[Conclusion] In MLC,CTL cells were decreased in SMC,especially in the high CEA value patients, showng the possibility of lower immunological defense ability than normal. The lower responsiveness to IL-2 in CTL was also recognized. It may be effective that the immuno-chemothrapy by injection via hepatic artery or portal vein using anti-cancer drugs and additional IL-2. This therapy will increase the CTL cells in SMC and make a good control in IL-2 R system, affecting the excellent results for the therapy in liver metastasis patients.